In most neurodegenerative disorders, including multiple sclerosis, Parkinson's disease, and Alzheimer's disease, a massive neuronal cell death occurs as a consequence of an uncontrolled inflammatory response, where activated microglia and its cytotoxic agents play a crucial pathologic role. Because current treatments for these diseases are not effective, several regulatory molecules termed "microglia-deactivating factors" recently have been the focus of considerable research. Vasoactive intestinal peptide (VIP) is a neuropeptide with a potent antiinflammatory effect, which has been found to protect from other inflammatory disorders, such as endotoxic shock and rheumatoid arthritis. In the present study, we investigate the effect of VIP on inflammation-mediated neurodegeneration in vitro and in vivo as well as on the putative neuroprotective effect of VIP on experimental pathological conditions in which central nervous system (CNS) inflammation is involved, such as brain trauma. The involvement of activated microglia and their derived cytotoxic products is also studied. VIP has a clear neuroprotective effect on inflammatory conditions by inhibiting the production of microglia-derived proinflammatory factors (tumor necrosis factor α, interleukin-1β, nitric oxide). In this sense, VIP prevents neuronal cell death following brain trauma by reducing the inflammatory response of neighboring microglia. Therefore, VIP emerges as a valuable neuroprotective agent for the treatment of pathologic conditions of the CNS where inflammation-induced neurodegeneration occurs.
diseases through the release of proinflammatory and/or cytotoxic factors, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-12, and nitric oxide (NO). Hence, it is important to unravel mechanisms regulating microglia activation of inflamed brain parenchyma to provide insights into efficient therapeutic intervention. Secretion of pro-inflammatory products is followed later by the production of anti-inflammatory cytokines such as IL-10 and transforming growth factor β. Because the intensity and duration of an inflammatory process depend on the local balance between pro-and anti-inflammatory factors, several regulatory molecules termed "microglia-deactivating factors" have been the focus of considerable research.
Vasoactive intestinal peptide (VIP), a 28-aa neuropeptide, elicits a broad spectrum of biological functions, including actions on natural and acquired immunity (2) (3) (4) . Although VIP affects a variety of immune functions, its primary immunomodulatory function is anti-inflammatory in nature. VIP has been shown to inhibit cytokine production and proliferation in T cells and to inhibit several macrophage functions, including phagocytosis, respiratory burst, and chemotaxis (2) (3) (4) , as well as LPS-induced IL-6, TNF-α, IL-12, NO, and chemokine production (5) (6) (7) (8) (9) (10) . Similarly, we have recently demonstrated that VIP acts as a potent microglia-deactivating factor by inhibiting the production of LPS-induced pro-inflammatory mediators in vitro (11, 12) . The inhibition of pro-inflammatory mediators is responsible, at least partially, for the protective effect of VIP in vivo in a murine model for septic shock (13) . In the present study, we investigate the effect of VIP on inflammation-mediated neurodegeneration in vitro and in vivo. We also investigate the putative neuroprotective effect of VIP on pathological conditions in which inflammation of the central nervous system (CNS) is involved, such as brain trauma. The involvement of activated microglia and their derived cytotoxic products is also studied.
MATERIALS AND METHODS

Reagents
Synthetic VIP, PACAP38, and the polyclonal anti-tyrosine hydroxylase (TH) antiserum were purchased from Calbiochem-Novabiochem (San Diego, CA). The VPAC1-agonist [K 15 , R 16 , L 27 ] VIP (1-7)-GRF (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) 
Cell cultures
Microglial cell cultures were prepared as described previously (12) . In brief, brain tissues of mesencephalon from 1-day-old Balb/c mice were dissected and dissociated after a 30-min trypsinization (0.25%) and were plated in 75-cm 2 Falcon culture flasks in Dulbecco's modified Eagle's medium (DMEM) high glucose formula (Life Technologies, Inc.) supplemented with 10% heat-inactivated fetal calf serum (FCS; Gibco-BRL, Gaithersburg, MD), containing 10 mM HEPES buffer, 1 mM pyruvate, 0.1 M nonessential aminoacids, 2 mM glutamine, 50 mM 2-mercaptoethanol, 100 U/ml penicillin, and 10 µg/ml streptomycin (complete medium). The medium was replenished 1 and 4 days after plating, and on day 8 of culture, plates were shaken for 20 min at a speed of 200 rpm in an orbital shaker to remove oligodendrocytes. On day 12 of culture, plates were shaken again for 2 h at a speed of 180-200 rpm. Harvested cells were filtered through a 20-µm nylon mesh, plated in a 60-mm petri dish, and incubated for 15 min at 37°C. After extensive washing with culture medium, adherent cells (microglia) were collected with a rubber policeman and centrifuged (1000 rpm, 10 min). Purified microglial cell cultures were composed of a cell population in which >98% stained positively with MAC-1 antibodies (Boehringer Mannheim Biochemicals, Indianapolis, IN) and <2% stained positively with antibodies specific to the astrocyte marker glial fibrillary acid protein.
Neuronal cell cultures were established following dispersion of fetal (day 15 of gestation Balb/c mice) cerebral cortices with trypsin (0.25%), as described previously (14) . In brief, cells (5×10 5 /0.5 ml) were plated onto collagen-coated wells of 24-well plates with complete medium. On day 5, the culture medium was replaced with complete medium containing 10% heatinactivated horse serum, uridine (33.6 µg/ml, Sigma) and fluorodeoxyuridine to suppress glial cell growth. After 24 h, cell cultures were replaced with complete medium containing 10% heatinactivated horse serum. Culture medium was changed every 4 days thereafter. On day 9 of culture, most neurons were growing in clusters (and some in single cells), with a confluent supporting layer of astrocytes. In the neuronal cell cultures, ~50% of the total cells were astrocytes, <2% were microglia, and <1% were oligodendrocytes (stained with anti-CNP), and ~50% were cortical neurons stained with antibodies specific to neuron-specific enolase with characteristic processes and birefringent cell bodies.
Microglial/neuronal cell cocultures were reconstituted by adding 10 5 purified mesencephalic microglia from day 12 cultures to cortical neuronal cell cultures derived from day 14 cultures, as described previously (15) . Microscopic evaluation revealed that microglial and neuronal cells were in a ratio of 1:2.
Primary mixed neuron-glia cultures were prepared from the brains of embryonic day 16 Balb/c mice. The whole brain was removed aseptically; the blood vessels and meninges were discarded; and the mesencephalic region was dissected, pooled, and mechanically dissociated in ice-cold calcium-and magnesium-free W3 buffer (15 mM HEPES pH 7.4, 145 mM NaCl, 5.4 mM KCl, 1 mM NaH 2 PO 4 , and 11 mM glucose). Cells (5×10 5 cells/well/0.5 ml) were seeded in 24-well poly-D-lysine-coated culture plates in complete medium supplemented with 10% heat-inactivated horse serum. The cultures were replenished with fresh medium at 1 and 4 days after plating.
Neuron-microglia cocultures were incubated with complete medium and stimulated with 100 ng/ml LPS in the presence or absence of VIP (from 10 −12 to 10 −6 M) at 37°C in a humidified incubator with 5% CO 2 . Cell-free supernatants were harvested at the designated time points and kept frozen (-20°C) until cytokine and nitrite determination.
Nitrite and cytokine assays
TNF-α activity was measured by cytotoxicity to L929 cells as described previously (16) . The production of NO was assessed as the accumulation of nitrite in the culture supernatants, using the colorimetric reaction with the Griess reaction as described previously (7).
Lactate dehydrogenase release assay in neuronal/microglial co-cultures
The supernatants from neuronal and microglial co-cultures were collected after 48 h of stimulation with LPS in the absence or presence of VIP for the measurement of the level of lactate dehydrogenase (LDH), an indicator of cell injury or death (17) . The LDH activity was measured with a diagnostic kit (Promega, Madison, WI). Total LDH release represents maximal lysis of target cells with 5% Triton X-100.
In vivo administration of LPS and VIP
Male Balb/c mice (8-to 10-wk old, 20 g body weight) were anesthetized with sodium pentobarbital (50 mg/kg) and positioned in a small-animal stereotaxic apparatus. LPS (5 µg) in a volume of 10 µl of saline in the presence or absence of VIP (10 µg) was injected into the third cerebral ventricle, using procedures described previously (18) (19) (20) . Control injections of saline alone were made under the same conditions. Alternatively, VIP was administered systemically by i.p. injections (50 µg/100 µl) daily for 3 days. At least eight animals were used for each experimental group.
Superoxide anion formation
Activation of microglia in cultures was determined by superoxide anion formation assessing reduction of nitroblue tetrazoilum (NBT, Sigma) as described previously (21).
Brain trauma
Brain trauma was caused in adult mice by vertical stab wound operations in the periventricular area by using a glass micropipette as described previously (18) (19) (20) . Medium (controls) or VIP (15 µg) was administered through micropipette at the same time of trauma induction.
In situ hybridization
Hybridization histochemical localization of TNF-α, iNOS, and IL-1β mRNA was performed on every sixth section of the whole rostrocaudal extent of each brain, using 35 S-labeled cRNA probes as described previously (22) (23) (24) . cDNA fragments containing the TNF-α (235-732), IL-1β (442-951), and iNOS (332-781) sequences were generated by RT-PCR of the mRNA of mouse macrophages, sequenced to confirm identity, and inserted into the pET plasmid. The respective reverse primers were attached with a T7 promoter sequence. Transcription of antisense and sense probes was carried out using the Riboprobe II Cure System Kit (Promega Biotec, Inc.) and [ 35 S]-UTP (25 µCi, Dupont NEN, Boston, MA). Radiolabeled probes were diluted in the riboprobe hybridization buffer and applied to brain sections (10 7 cpm/ml). Unspecific hybridization was determined by parallel hybridization of adjacent sections with labeled probe and an excess of unlabeled probe (10-100 times), pretreatment of sections with RNase before the hybridization, or in situ hybridization with a sense probe. In all these negative controls, no significant hybridization signal was observed.
To confirm that Mac-1 + cells in brain express TNF-α, iNOS, and IL-1β mRNA, in situ hybridization was followed by immunohistochemistry with anti-Mac-1 antibody as described previously (24) .
Immunocytochemistry
Cell cultures were fixed in 3.7% formaldehyde and immunostained as described previously (25) . For in vivo studies, animals were anesthetized with sodium pentobarbital and then perfused transcardially with saline, followed by 4% paraformaldehyde in PBS. Brains were removed and post-fixed overnight in 4% paraformaldehyde solution. Coronal sections (35 µm) were cut using a microtome and immunostained as free-floating tissue sections (25) . Every sixth serial section was selected and processed for immunohistochemistry.
Neurons were identified with a monoclonal antibody to MAP-2 (Roche Molecular Biochemicals) and an antibody against the neuron-specific nuclear protein (NeuN, Chemicon, Temecula, CA). Dopaminergic neurons were stained with a polyclonal anti-TH antibody. Microglia were visualized by staining with the anti-Mac1 antibody.
In brief, cultures or brain sections were blocked with 0.4% Triton X-100, 1% BSA, and 4% normal serum in PBS, followed by an overnight incubation with one of the primary antibodies (anti-MAP-2, 5 µg/ml; anti-NeuN, 1 µg/ml; anti-TH, 1:30; or anti-Mac1, 5 µg/ml). Afterward, cells or sections were incubated with 1% H 2 O 2 , followed by incubation with the appropriate biotinylated secondary antibodies and then visualized using the avidin-biotin-peroxidase complex method with DAB as the chromogen. The sections were coded, analyzed in a Zeiss Axioplan microscope, and recorded using a CCD camera and the NIH Image computer software. The number of MAP-2 + , TH + , and NeuN + neurons and Mac-1 + microglia in wells and in different brain areas was counted in the various experimental groups by using an optical fractionator method. This method for cell counting is not affected by either the volume of reference (different brain areas) or the size of the counted elements (neurons or microglia). Infiltrated leukocytes were visualized using the FITC-labeled anti-CD16/CD32 antibody (1:100, PharMingen) and visualized with a fluorescence microscope.
High-affinity [ 3 H]dopamine uptake assay
Uptake of radiolabeled dopamine was performed as described previously (25) . Cultures were washed with Krebs'-Ringer's buffer (120 mM NaCl, 4.7 mM KCl, 1.3 mM EDTA, 1.8 mM CaCl 2 , 1.2 mM MgSO 4 , 16 mM NaH 2 PO 4 , 16 mM Na 2 HPO 4 , and 1 mg/ml glucose), followed by incubation for 45 min at 37°C with 0.5 µCi [
3 H]dopamine and 1 µM unlabeled dopamine (Sigma) in Krebs'-Ringer's buffer. Nonspecific uptake was determined by the addition of 10 µM mazindol. Afterward, the cultures were washed three times with ice-cold buffer and then solubilized with 1 N NaOH. The lysate was mixed with scintillation fluid, and radioactivity was counted in a scintillation counter. Specific uptake was determined by subtracting the nonspecific counts.
RESULTS AND DISCUSSION
Microglia are the primary immune cells of the CNS and are involved in the pathogenesis of several neurological disorders, including neurodegenerative diseases (1) . In response to injury, infection, or inflammation, microglia readily become activated, secreting a host of immunomodulatory and cytotoxic factors, among which a few are suggested to play a role in brain tissue repair (1), whereas others, including proinflammatory cytokines and reactive nitrogen and oxygen intermediates, are thought to be destructive and involved in neurodegeneration through mechanisms not fully understood. Microglia are present in large numbers within the brain, but they are not distributed with an uniform density or morphology in all major divisions of the brain (26) , and it has been described that neurons in various brain regions are differentially susceptible to inflammation-related degeneration (25) . Among several regions examined, neurons in the mesencephalic region are more sensitive to bacterial endotoxin-induced neurotoxicity, and this region-specific susceptibility to LPS-induced degeneration is most likely attributable to the abundance of microglia. Because VIP has been shown to inhibit endotoxin-induced production of proinflammatory mediators by activated microglia (11, 12) , this neuropeptide is a plausible candidate for neuroprotection under inflammatory conditions.
VIP protects from inflammation-induced neurodegeneration in vitro by inhibiting microglial activation
We first investigated the effect of VIP on neuronal death induced by the bacterial endotoxin LPS in vitro in mixed neuron-microglia cultures. Mouse embryonic neurons were co-cultured with neonate mesencephalic microglial cells and were stimulated with LPS in the presence or absence of VIP. LPS treatment of co-cultures resulted in a profound neuronal cell loss (determined by immunostaining against the neuronal cytoskeletal protein MAP-2), and most of the few remaining cells displayed shortened neurites compared with the control cultures (Fig. 1A) . VIP addition to co-cultures drastically inhibited LPS-induced neural mortality and change in morphology (Fig. 1A) . A similar neuroprotective effect of VIP was observed in primary mixed glia-neuron cultures established using embryonic mouse brain regions from mesencephalon, where VIP inhibited, in a dose-dependent manner, the LPS-induced LDH release into the medium (Fig. 1B) . The VIP neuroprotective effect was also confirmed by immunostaining of MAP-2 + neurons in these cultures (not shown), and it was especially relevant when dopaminergic neurons (tyrosine hydroxylase TH + neurons) were analyzed in these cultures, instead of total neuronal populations (MAP-2 + cells). LPS caused a dramatic loss of TH + neurons in mesencephalic mixed neuronal-glial cultures (Fig. 1C) , confirmed by a decrease in the [ 3 H]-dopamine uptake (Fig. 1D) . VIP protected dopaminergic cells from LPS-induced inflammation (Fig. 1C, 1D ). VIP-mediated neuroprotection of dopaminergic neurons has important therapeutic perspectives, because the loss of these neurons in substantia nigra is one of the causes of Parkinson's disease. In fact, we have recently shown that VIP acts as a neuroprotective agent in an experimental model of Parkinson's disease (27) .
LPS-induced neurodegeneration was associated with, and was probably mediated by, an increased microglial activation, characterized by changes in morphology from a ramified resting state to an amoeboid appearance, with an increase in the expression of Mac-1 + microglial cells, in free-radical production, and in the production of the proinflammatory mediators TNF-α and NO (Fig. 1E) . Involvement of activated microglia and their derived cytotoxic factors in inflammation-induced neurodegeneration is suggested by the facts that LPS failed to induce cell loss in cultures with neurons alone and that cell-free supernatants from LPS-stimulated microglia cultures induced a significant cell death in neurons cultured alone (Fig. 1F) . Furthermore, addition of neutralizing antibodies against TNF-α and IL-1β (10 µg/ml) to microglial-neuronal co-cultures significantly reduced LPS-induced MAP-2 + cell loss (% inhibition of cell loss: 46, 24, and 68 for anti-TNF, anti-IL-1, and both, respectively). Treatment with VIP inhibited in a dose-dependent manner all these hallmarks of LPS-induced microglial activation and the production of TNF-α and NO (Fig. 1E) .
A similar "microglial-deactivating" action of VIP was observed in mixed neuron-glial cultures prepared from embryonic mesencephalic tissue (Table 1 ). The VIP dose-response curve observed for the neuroprotective effect correlates with that for the microglial deactivation, suggesting that VIP could mediate its protective effect through its action on microglia activation. This is correlated by the fact that treatment of neuronal cultures with conditioned medium from LPSactivated microglia cell cultures treated with VIP did not show significant neuronal death (Fig.  1F ). In addition, the neuroprotective effect of VIP in LPS-treated neuronal-microglial cocultures was partially reversed by the addition of TNF-α and IL-1β, or of conditioned medium from LPSstimulated microglial cultures (Fig. 1G) , suggesting that the neuroprotective effect of VIP against endotoxin could be mainly mediated through the inhibition on the production of microgliaderived cytotoxic factors.
Next we investigated whether the inhibitory effect of VIP could be related to occupancy of specific receptors. VIP belongs to the family of peptides that includes pituitary adenylate cyclase-activating polypeptide (PACAP). Both peptides share several functions, exerted through a family of receptors consisting of VPAC1, VPAC2, and PAC1 (28) . RT-PCR analysis indicates that murine primary microglia express both PAC1 and VPAC1 mRNA (11) . In contrast, VPAC2 mRNA was not expressed even following LPS activation. To determine which of the VIP/PACAP receptors is involved in the inhibition of inflammatory cytokine production, we used specific receptor agonists. The effects of a VPAC1-agonist (29); a VPAC2 agonist (Ro 25-1553) (30) ; and maxadilan, a PAC1 agonist (31), were tested. PACAP and the VPAC1 agonist, but not the VPAC2 or the PAC1 agonist, inhibited LPS-induced neurodegeneration and microglia activation, with a potency similar to that of VIP (Table 1 ). These results indicate that both neuropeptides exert their action primarily through VPAC1 and are in agreement with previous works describing the inhibitory effect of VIP on the production of microglia-derived proinflammatory factors (11, 12) . In addition, the specificity of VIP was also confirmed by the fact that other members of the VIP family, such as secretin and glucagon, did not show any significant effect (Table 1) .
VIP prevents neurodegeneration and microglial activation in vivo
We next investigated whether the neuroprotective effect of VIP under inflammatory conditions is also observed in vivo. LPS was injected in the third ventricle (i.c.v.) of adult mouse brains. Different doses of VIP were administered concomitantly with LPS. Neurodegeneration in different mesencephalic areas was determined by immunostaining of brain sections with an antibody against the NeuN. LPS administration caused a dramatic NeuN + cell loss in certain brain areas, especially in periventricular nucleus (PVN), caudate putamen (CP), and substantia nigra (SN) (Fig. 2) . In contrast, other brain areas such as cortex and hippocampus were not susceptible to LPS-induced neurotoxicity (data not shown). The LPS-induced neurodegeneration was accompanied by massive microglia activation and by an increase in the expression of TNF-α, IL-1β, and iNOS mRNA in the same areas (Fig. 2) . Phenotypic analysis by double in situ hybridization and immunocytochemical examination showed that the majority of cells expressing these inflammatory mediators are microglia (data not shown). Local VIP administration (i.c.v. injection) prevented LPS-induced neurodegeneration; microglia activation; and TNF-α, IL-1β, and iNOS expression in PVN, CP, and SN (Fig. 2) . The VIP effect was dose-dependent (neuroprotective effect on PVN neurons for 15, 5, 1, and 0.1 µg VIP was 87±6, 66±8, 32±4, 3±2, respectively). Interestingly, systemic VIP administration was also neuroprotective, although VIP doses 15-fold higher than that local VIP administration were needed to obtain similar effective results (i.p. injection of 50 µg VIP twice daily for 2 days resulted in a neuroprotective effect on PVN and CP neurons of 77±8 and 73±6, respectively).
During endotoxemia, caused by a systemic Gram-negative bacteria infections, in addition to the clinical manifestations characterized by hyperventilation, hypercoagulation, fever, cachexia, hypotension, and multiple organ failure, certain brain regions, especially the circunventricular organs and the parenchymal structures surrounding them, are seriously affected by endotoxin, causing a massive neurodegeneration. In this sense, the anti-inflammatory action of VIP in CNS described in the present study could contribute to its preventive effect on systemic endotoxemia (13) . The blood-brain barrier, normally present in these areas as tight junctions between endothelial cells, is largely compromised under inflammatory conditions, explaining the diffusion of large molecules (such as VIP) into the perivascular region.
Neuroprotective role of VIP following brain trauma
Next, we were interested in the study of the possible therapeutic effect of VIP in brain trauma, a pathological condition associated with inflammation (1). The increase in the levels of proinflammatory cytokines is a normal and early feature of the CNS response to trauma (32) (33) (34) . However, it remains controversial whether inflammation in the injured CNS serves a beneficial or detrimental purpose (35, 36) . Several reports demonstrated that the administration of inflammatory cytokines to injured areas was neuroprotective and/or promoted axonal regeneration (35, 36) . It has been reported that blood-derived macrophages modify the properties of CNS white matter near mechanical lesions, converting a nonpermisive state to one promoting axonal growth (37) . In contrast, a number of studies have shown the involvement of proinflammatory mediators such as TNF-α, IL-1β, and NO in the mediation of neuronal and oligodendroglial death (reviewed in refs. 1 and 35) . Also, treatment with anti-inflammatory agents limits CNS damage and improves recovery after blunt spinal cord trauma (38) , and there is a positive correlation between the number of macrophages/microglia and the degree of tissue damage (39) .
It has been proposed that these differences regarding the role of inflammation in CNS could be region-or structure-specific and/or -dependent on the varied stages of neuronal degeneration (40, 41) . We used a model of adult mice stab wound brain trauma in the periventricular area. Medium (controls) or VIP was administered at the injury site through a micropipette at the time of trauma induction. Different times after injury, neuronal cell loss, inflammatory cell invasion, and microglia activation were determined. Following mechanical injury, several events occurred at the injury site, that is, dramatic neurodegeneration, recruitment of mononuclear phagocytes, a significant increase in activated microglia, and increased production of TNF-α and IL-1β (Fig.  3) . Treatment with VIP significantly reduced all these events (Fig. 3) . The source of inflammatory cytokines in the CNS following trauma remains unresolved. Infiltrating leukocytes are obvious candidates, but the influx of leukocytes in the CNS is delayed in response to an acute insult in comparison to other tissues. Thus, neutrophils do not infiltrate appreciably until ~6 h after lesion, whereas T lymphocytes and monocytes appear between 12 and 24 h or latter (42) (43) (44) , suggesting that the CNS mounts an early and intrinsic inflammatory response upon trauma, before leukocyte infiltration occurs. Microglia have been proposed as the origin of the early increase in CNS inflammatory cytokines following injury (33, 34) . We propose that VIP reduces neuronal cell loss in the vicinity of the lesion site through the inhibition of microglial-derived proinflammatory mediators such as TNF-α and IL-1β and of chemokines (11) responsible for the inhibition of the influx of blood-derived leukocytes into the parenchyma surrounding the injured region. In addition, although it is unlikely that the reduction of LPS-induced microglia activation by VIP is secondary to the attenuation of neuronal loss rather than the reverse (Fig. 1) , a direct action of VIP on neurons cannot be ruled out. Finally, the involvement of astrocytes in the mediation of VIP, although minimal, should not be discounted, because VIP slightly reduced the trauma-induced astrogliosis (data not shown). In addition, neurotrophic effects mediated through astrocytes cannot be excluded. In this sense, a neuroprotective action of VIP in response to different neuronal insults, by inducing the production of neuroprotective factors (i.e., ADNF) by astrocytes, has been described (45, 46) . Therefore, the administration of VIP following acute trauma of the CNS could be beneficial, at least in certain regions of the brain. Our study also suggests possible therapeutic uses of VIP in certain brain disorders such as multiple sclerosis, Parkinson's and Alzheimer's diseases, and AIDS dementia, in which inflammatory responses play a major role. a Primary mixed neuron-glia cultures were prepared from mesencephalic tissues of embryonic day 16 mice. Cultures were treated for 72 h with LPS (100 ng/ml) in the absence or presence of VIP, PACAP, VPAC agonists, secretin, or glucagon (10 -8 M). Neuronal cell injury or death was determined by measuring LDH secretion to the culture supernatants. The number of Mac1 + cell bodies and the production of TNF-α in cultures were determined. Data represent the percentage of inhibition calculated by comparison with controls containing LPS alone. Each result is the mean ±SD of four experiments. into adult mice in the absence or presence of VIP (15 µg, 5 nmol). After 7 days, the brains were removed, and the tissue sections through the areas of interest (mesencephalic region at the level of PVN is shown in the micrographs) were immunostained for the neuronal-specific protein NeuN and the activated microglia-specific Mac1. Twenty-four hours after injection, TNF-α, IL-1β, and iNOS mRNA expression was determined by in situ hybridization in the same areas. The number of positive cells for each marker per square millimeter in each mesencephalic area (PVN, periventricular nucleus; CP, caudate putamen; SN, substantia nigra) is shown (mean ±SD from eight animals used for each treatment). 
